MedTrace Logo

Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study.

NCT01899638 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-06-07

No results posted yet for this study

Summary

This study is to assess the pharmacokinetics (PK), safety and tolerability of UMEC (62.5µg and 125µg) and VI (25µg) as monotherapies and combinations in healthy Chinese subjects.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

UMEC/VI 125/25 mcg

Combination in high dose

DRUG

UMEC/VI 62.5/25 mcg

Combination in low dose

DRUG

UMEC 125 mcg

LAMA mono in high dose

DRUG

UMEC 62.5 mcg

LAMA mono in low dose

DRUG

VI 25 mcg

LABA mono

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-05-20
Primary Completion
2013-07-25
Completion
2013-07-25

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01899638 on ClinicalTrials.gov